Luminary Group’s Post

🚀 Recent Pharma Industry Insights 🚀 1. 💼 Avalo Therapeutics appoints Ms. Mittie Doyle as new COO, enhancing leadership. 2. 🧬 Genomics plc and Vertex Pharmaceuticals extend collaboration for CF therapies, boosting research. 3. 🏭 Kindeva Drug Delivery's Woodbury facility achieves FDA VAI status, ensuring quality. 4. 🔬 Sionna Therapeutics secures CF rights from AbbVie, advancing treatment options. 📌 Read more news- https://lnkd.in/dh36nZ8Y 💬 Join the Conversation! Which news excites you the most? Share your thoughts below! 🗣️ 🔗 Stay tuned for more updates and exclusive content! #PharmaNews #PharmaNow #IndustryUpdate #HealthcareInnovation #StayTuned

Here's Catenion's 10-year longitudinal study systematically clustering top biopharma companies into six performance phenotypes and dissecting patterns, key factors that positively influence R&D productivity. Key Takeaways: ♦ Creativity and innovation are easier to orchestrate in smaller units with less bureaucracy and high individual accountability ♦ Going deep vs broad: Having a solid TA focus and thinking well in advance about the ability to create spin off indications should not be neglected ♦ Focusing on key high-value assets, and ideally, having a 'pipeline in a product' is the best thing for R&D productivity ♦ Striking a balance between relying on core internal strengths for organic growth and leveraging external innovation through deals and M&As needs to be achieved You can read the full report here: https://lnkd.in/gnhMzesy

Cutaneous Lupus Erythematosus Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Gilead, Priothera, Sanofi, Merck, Centessa #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech

The following week saw more acquisitions in biotech. The #market is buzzing and bobbing for more acquisitions. ➡ The hero of today's post is seladelpar. Two-year results on the safety and efficacy of this drug were published in January. No serious treatment-related side effects were observed while the therapy was shown to be effective, which convinced Gilead Sciences to deepen its portfolio with a drug that could be FDA approved for the treatment of primary biliary cholangitis (PBC) as early as this August. CymaBay Therapeutics ensured that FDA's Breakthrough Therapy Designation, the European Medicines Agency's PRIME status, and the orphan drug designations granted by both regulatory agencies and can now reap the benefits ($4.3 billion). ➡ The latest news, however, points to GSK acquiring Aiolos Bio for $1.4 billion. The key asset of the deal is a monoclonal #antibody specific for TSLP, which has demonstrated high potency and extended half-life in preclinical studies and preliminary clinical trials. I'll keep a close eye on further #business deals and bring you the most interesting news from this world.

What are the factors that drive pharma R&D Productivity? Which pharma companies have done it best? Catenion has been systematically analyzing R&D Productivity for over 10 years. Now, our team has conducted a longitudinal study to answer these key questions, outlined by Catenion's Senior Partner Markus Thunecke. 💡A must-watch for everyone in the biopharma industry. Explore the in-depth report here: https://lnkd.in/gnhMzesy Companies featured: Novo Nordisk, AstraZeneca, Eli Lilly and Company, Novartis, Roche, Eisai US, Daiichi Sankyo, Inc., Pfizer, Sanofi, UCB, Merck KGaA, Darmstadt, Germany Bayer, Otsuka Pharmaceutical Co., Ltd., Takeda, Biogen, Gilead Sciences, AbbVie, Merck, Bristol Myers Squibb, GSK, Amgen, Johnson & Johnson, Astellas Pharma #Catenion #BiophamaConsulting #BiopharmaInnovation #RnDProductivity

What are the main dimensions driving successful businesses in Biopharma? Check out Catenion’s learnings from a 10-year longitudinal study on R&D productivity to find out. Get in touch if you want to hear more!

🗨Richardson Round Up 💬 I hope everyone has had a great start to their week! Let's have a look at what's been going on since last time. 🤝 Xyphos Biosciences Inc., (a wholly owned subsidiary of Astellas Pharma Inc.) and Kelonia Therapeutics have entered into a research collaboration and license agreement to develop novel Immuno-Oncology therapeutics. ✅ VantAI and Bristol Myers Squibb have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest. VantAI's mission is to unlock the potential of proximity modulation as a powerful tool against therapeutic targets. ⬆ Telix Pharmaceuticals Limited has agreed to acquire QSAM Biosciences, Inc. The acquisition of QSAM provides Telix with an additional near-term therapeutic pipeline asset. 🔰 BridgeBio Pharma Inc. and Kyowa Kirin Co., Ltd. have announced a partnership where BridgeBio’s affiliate, QED Therapeutics, grants Kyowa Kirin an exclusive license to develop and commercialize infigratinib for achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan. #biotech #pharma #pharmaceuticals #biosciences #therapeutics

Exploring breakthroughs in the #GenitalHerpes Market: Revolutionizing treatment and management for millions worldwide. As the pharmaceutical landscape continues to evolve, we're at the forefront of innovative solutions, driving research, and development to address unmet medical needs in Genital Herpes. The leading Genital Herpes Companies working in the market include AiCuris Anti-infective Cures AG, United Biopharma, Heidelberg ImmunoTherapeutics GmbH, Genocea Biosciences, Agenus, Fresh Tracks Therapeutics, Sanofi, GSK, and others. Our commitment to patient-centric care and scientific excellence propels us toward transformative therapies, improving quality of life, and advancing the standard of care. Join us as we navigate this dynamic market, fostering collaboration, and shaping the future of #GenitalHerpestreatment Together, we're making strides in disease understanding, therapeutic advancements, and ultimately, empowering patients to live healthier, more fulfilling lives. Get More Insights @ https://lnkd.in/eE_TW6dB #GenitalHerpes #MedicalInnovation #HealthcareAdvancement #PatientCare #ResearchAndDevelopment

Pharma companies are gearing up to invest $302 billion in R&D by 2028, but the returns are the real question. With oncology drugs only making a modest appearance, the landscape is changing, highlighting diseases like Alzheimer's and schizophrenia. The top 10 projects promise a net present value of $79.1 billion and potential product revenue of $19.4 billion globally by 2028. However, drug development costs are rising, posing challenges and uncertainties. #pharma #rnd #drugdevelopment #biopharma #investment #healthcare https://lnkd.in/eM5dHNKq

A lot happened this week but one (actually two) event(s) topped it all: AbbVie made a big M&A splash by successively acquiring ImmunoGen, Inc. and Cerevel Therapeutics for a combined deal value of $19bn. As mentioned by David Wainer at The Wall Street Journal: "While the two deals came in quick succession, they both fit pharma’s Goldilocks mold of deal making: It has to be big enough to make a difference, but not too big to break the bank and attract antitrust scrutiny." ➡ WSJ article: https://lnkd.in/ekFUDy6N As always, buying either an early commercial (i.e., ImmunoGen, Inc.) or a late stage biotech company (i.e., Cerevel Therapeutics) is ALWAYS a high-risk bet, especially in the indications of interest of both target companies. Three things are certain: 1️⃣ M&A is firmly back on the table, especially has immune-disease Humira has just started facing pressures from biosimilars in the US 2️⃣ Many times in its history, experts have prophetized the end of AbbVie, due to its over-reliance on Botox and Humira. Some will remember that was partly the back-story of the company's spin-off from Abbott... Doomsayers: please be kind. 3️⃣ AbbVie has a great track-record in M&A. Let's not forget that it bought Humira from BASF for $6.3bn in 2000, a deal which was dubbed too expensive at the time. We all know what happened next... Humira became the largest selling drug of all time! #lifesciences #biotech #mergersandacquisitions